IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM)
Preliminary clinical activity observed in primary UM, including tumor shrinkage...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Eye Cancers | Melanoma | Neoadjuvant Therapy | Pharmaceuticals | Skin Cancer | Uveal Melanoma